Cell Genesys to Present at the Rodman and Renshaw 9th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Oct. 30 CellGenesys, Inc. (Nasdaq: CEGE), today announced that Sharon E. Tetlow, seniorvice president and chief financial officer of Cell Genesys, will present acompany update at the Rodman and Renshaw 9th Annual Healthcare Conference inNew York City on Tuesday, November 6, 2007, at 5:05 p.m. ET.

A live audio webcast of the presentation will be accessible through theInvestor Relations section of the Cell Genesys website,http://www.cellgenesys.com. If you are unable to listen to the live webcast,it will be archived on the site for at least 72 hours following thepresentation. To access the replay, go to the Investor Relations section ofthe website.

Cell Genesys is focused on the development and commercialization of novelbiological therapies for patients with cancer. The company is currentlypursuing two clinical stage product platforms -- GVAX(TM) cancerimmunotherapies and oncolytic virus therapies. Ongoing clinical trialsinclude Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and aPhase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. CellGenesys continues to hold an equity interest in its former subsidiary,Ceregene, Inc., which is developing gene therapies for neurodegenerativedisorders. Cell Genesys is headquartered in South San Francisco, CA and hasits principal manufacturing operation in Hayward, CA. For additionalinformation, please visit the company's website at http://www.cellgenesys.com.Contact: Susan Ferris Investor Relations 650-266-3200

SOURCE Cell Genesys, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...